virosecurinine: isomer of the securinine group of alkaloids; isolated from plant Securinega virosa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Securinega virosa | species | [no description available] | Phyllanthaceae | [no description available] |
| ID Source | ID |
|---|---|
| PubMed CID | 928095 |
| CHEMBL ID | 1495075 |
| MeSH ID | M0059745 |
| Synonym |
|---|
| MLS000574925 |
| smr000156309 |
| nsc-107414 |
| virosecurinine |
| 6704-68-3 |
| nsc 107414 |
| securinan-11-one, (2alpha,7beta,9beta)- |
| virosecurinin |
| securinan-11-one, (2-alpha,7-beta,9-beta)- |
| 2-alpha,7-alpha-securinine |
| (2-alpha,7-beta,9-beta)-securinan-11-one |
| AC-11202 |
| HMS2208H24 |
| unii-d05x6h4208 |
| d05x6h4208 , |
| CHEMBL1495075 |
| AC-34984 |
| AKOS025401340 |
| SR-01000721464-4 |
| SR-01000721464-5 |
| sr-01000721464 |
| SR-01000721464-6 |
| 2.alpha.,7.alpha.-securinine |
| securinan-11-one, (2.alpha.,7.beta.,9.beta.)- |
| (+)-virosecurinine |
| 8h-6,11b-methanofuro(2,3-c)pyrido(1,2-a)azepin-2(6h)-one, 9,10,11,11a-tetrahydro-, (6r,11as,11br)- |
| 8h-6,11b-methanofuro(2,3-c)pyrido(1,2-a)azepin-2(6h)-one, 9,10,11,11a-tetrahydro-, (6r-(6.alpha.,11a.beta.,11b.alpha.))- |
| d-securinine |
| (6r,11as,11br)-9,10,11,11a-tetrahydro-8h-6,11b-methanofuro(2,3-c)pyrido(1,2-a)azepin-2(6h)-one |
| DTXSID901316136 |
| (1r,2s,8r)-14-oxa-7-azatetracyclo[6.6.1.01,11.02,7]pentadeca-9,11-dien-13-one |
Virosecurinine is a major alkaloid of the plant Securinega suffruticosa. It has been found to be a potent agent in inducing the differentiation of cancer cells.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Virosecurinine is a major alkaloid of the plant Securinega suffruticosa and has been found to be a potent agent in inducing the differentiation of cancer cells. " | ( Induction of human chronic myeloid leukemia K562 cell apoptosis by virosecurinine and its molecular mechanism. Chen, D; Han, S; Ji, Z; Li, M; Wang, Y; Ye, W; Zhang, G, 2014) | 2.08 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 15.8489 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| 67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 14.1254 | 0.0006 | 18.4198 | 1,122.0200 | AID2669 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 10.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 10.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 10.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| geminin | Homo sapiens (human) | Potency | 13.0801 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 15.8489 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 25.1189 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.46) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||